Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation
Chi Kin Wong(Lunenfeld-Tanenbaum Research Institute), Daniel J. Drucker(Mount Sinai Hospital), Brent A. McLean(University of Toronto), Rola Hammoud(University of Toronto), Randy J. Seeley(University of Cincinnati), Laurie L. Baggio(Sinai Health System), Theodore J. Brown(University of Toronto), Julian M. Yabut(Lunenfeld-Tanenbaum Research Institute), Jacqueline A. Koehler(Mount Sinai Hospital), Nikolaj Rittig(Aarhus University Hospital)
Cited by 251
Related Papers
Joint international consensus statement for ending stigma of obesity
|Nature Medicine|2020|1.1k
The role of gut hormones in glucose homeostasis
|Journal of Clinical Investigation|2007|611
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
|Endocrine Reviews|2014|602
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
|Diabetes Care|2003|578
Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
|Journal of Clinical Investigation|2014|396